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(QALYs) gained. Model probabilities were obtained from a systematic review involv-
ing international published trials. Comparators used in the assessment were lorazepam 
(6 mg/day); alprazolam (1.5 mg/day); venlafaxine (75 mg/day) and pregabalin (150–
600 mg/day). Resource use and costs were obtained by a panel of Mexican experts 
through the Delphi technique and ofﬁ cial institutional databases. Costs include out-
patient and inpatient services, drug, procedures, etc. The model was validated accord-
ing to international guidelines. One-way and probabilistic sensitivity analyses were 
performed and acceptability curves were constructed. RESULTS: Pregabalin had the 
highest percentage of patients with over 50% reduction on the HAM-A scale (64.7%);
followed by venlafaxine (54.1%), lorazepam (40.8%) and alprazolam (38.2%). 
Regarding QALYs the highest results corresponded to pregabalin (0.1838QALYs);
followed by venlafaxine (0.1787QALYs), alprazolam (0.1776QALYs) and lorazepam 
(0.1753QALYs). The 12-week expected mean costs per patient were US$1525.0 o
531.3; US$1532.6 o 548.3; US$1582.2 o 573.0 and US$1,635 o 604.6; respectively
following the last order above. The ICER for pregabalin vs. venlafaxine (baseline) was
US$465.7 for HAM-A and US$26,075.7 for QALYs. Pregabalin dominated lorazepam 
and alprazolam (p  0.05). First-order Monte Carlo sensitivity analyses showed results 
robustness and that pregabalin was the most cost-effective therapy using international 
thresholds. CONCLUSIONS: Pregabalin showed to be a cost-effective and cost-saving
therapy in the management of Mexican patients with GAD.
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OBJECTIVES: The present cost-effectiveness analyses compare escitalopram versus 
duloxetine and generic venlafaxine in second-line MDD treatment, to inform decision-
making on efﬁ cient second-line therapy choice. METHODS: A decision model was 
based on second-line MDD treatment patterns (6-month timeframe). Effectiveness 
outcomes were sustained remission (the Montgomery-Asberg Depression Rating Scale 
(MADRS) a12 at 2 months, sustained till the end of, month 6) and quality-adjusted
life years (QALY). Total cost included health care and absenteeism costs. Clinical
inputs were derived from pooled analyses of randomized clinical trials on the second-
line patients subgroup. Health care resource utilization was assessed from a Swedish
observational cohort (HEADIS) and UK General Practice Research Database (GPRD). 
Utility estimates were based on HEADIS and US panel survey. Unit costs were from
standard sources. Due to unavailability of generic venlafaxine unit cost, it was 
assumed equal to that of escitalopram in Scenario 1, and 5% of the brand venlafaxine
cost in Scenario 2. RESULTS: Over 6 months, a sustained remission rate was 56% 
for escitalopram and 38% for SNRIs (18% difference, 95% Credibility Interval (CrI) 
0.8% to 32.9%)). The incremental QALY for escitalopram versus both comparators
was 0.024 (95% CrI 0.006 to 0.042). Per patient savings with escitalopram versus 
venlafaxine were 670 USD (95% CrI 6689 to 4481) in Scenario 1 and US$565 USD
(95% CrI 6588 to 4583) in Scenario 2. Versus duloxetine, savings were USD615, 
95% CrI (6670 to 4554). With willingness to pay 42,500 USD (equivalent to 350,000
SEK) per QALY, escitalopram was cost effective versus venlafaxine with probabilities 
86% and 61.7% in Scenarios 1 and 2, respectively, and with 85.4% probability versus 
duloxetine. CONCLUSIONS: Escitalopram is cost-effective versus venlafaxine and 
duloxetine in second-line treatment of MDD in Sweden. The higher sustained remis-
sion rate and QALYs are associated with cost savings and support use of escitalopram 
following failure of ﬁ rst-line treatment.
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OBJECTIVES: Many patients on antidepressants are not responsive to ﬁ rst-line
therapy (‘treatment-resistant’ depression [TRD]) and can undergo switches and opti-
mizations to discover a beneﬁ cial therapeutic regimen. While patients with more
complex forms of TRD have higher costs than non-TRD patients, little is known about
the cost effects for patients along a gradient of TRD classiﬁ cations (from moderate to
complex). METHODS: Patients aged 18–64 years in employer-sponsored plans with 
at least three years of continuous medical and prescription coverage and at least one 
antidepressant prescription were found in the 2000–2006 MarketScan Database (n 
78,476). An MGH TRD scale value (range from 0 to 16.5) was calculated for each
patient and a value exceeding 3.5 indicated TRD. Twelve-month direct medical and 
prescription drug expenditures for patients with TRD (n  22,593) were compared to
expenditures among an equal number of propensity-score matched patients with non-
TRD depression. Propensity scores were estimated via demographic characteristics and 
case-mix. Generalized linear models (gamma family and log link) controlled for 
demographic and case-mix factors. RESULTS: Average 12-month direct medical care
and prescription drug expenditures were almost 40% higher for TRD ($9470) com-
pared to matched non-TRD patients ($6813) (p  0.01). A one-unit increase in TRD 
score was associated with a $772 increase in annual costs (p  0.01). Compared with
a matched group of non-TRD patients, annual costs for patients were higher in each
MGH score catergory: 3.5–4, 23.6%; 4.5–5, 32.9%; 5.5–6, 44.6%; 6.5, 61.1% (all 
p  0.01). CONCLUSIONS: TRD is a costly disorder and merits consideration as
interventions are developed to manage the burden of disease and improve productivity. 
Even patients with less complex forms of TRD have costs far in excess of those without
TRD. Dichotomous deﬁ nitions of TRD may not be adequate; a gradient from moder-
ate to complex TRD may be more useful for providers and insurers.
PMH27
INPATIENT COST OF SCHIZOPHRENIA TREATMENT IN TURKEY
Ayer A1, Sariöz F2, Kanbur B2, Yapici A1, Mizrak Demet S1, Tatar F2
1Manisa Mental Diseases Training and Research Hospital, Manisa, Turkey, 2Janssen-Cilag, 
Istanbul, Istanbul, Turkey
OBJECTIVES: Schizophrenia, inﬂ uencing approximately 1% of the population, is a
chronic psychiatric disease with a substantial health and economical burden for 
patients, care givers, and society. Despite this, however, its economic burden is often
overlooked and/or not widely known in many countries. This study aims at estimation 
of cost of schizophrenia treatment in an inpatient facility in Turkey. METHODS: The 
study has been conducted in Manisa Mental Diseases Training and Research Hospital, 
one of the largest of its type in Turkey. Electronic hospital records of 4177 schizo-
phrenia patients between June 2006 and June 2007 were retrospectively analyzed to 
calculate the total schizophrenia treatment cost per hospitalization where only direct 
costs were included. Cost items included in the analyses were antipsychotic and con-
comitant medication costs, adverse event treatment costs, bed costs, and laboratory/
radiological examination costs. Average length of stay per hospitalization was calcu-
lated. Results were presented as average daily and total costs of treatment per hospi-
talization. Composition of the total cost was also presented. RESULTS: Mean length 
of stay per hospitalization was 30.80 o 17.18 days. Mean daily total cost was TL
52.68 o 41.30. Mean total treatment cost per hospitalization was TL 1431.86 o
798.74. Costs for antipsychotic drugs, concomitant medications, adverse event 
treatment, bed, and laboratory/radiological examinations were 31%, 2%, 1%, 40%, 
and 26% respectively. CONCLUSIONS: The share of drug costs may be relatively 
higher than they are in other countries due to relatively lower costs for non-drug
cost items in Turkey. This may also stem from the case-mix in this hospital that may 
care more for severe cases needing tertiary care. This study may stimulate further
studies which would help to generate a fuller picture of economic burden of schizo-
phrenia in Turkey.
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OBJECTIVES: Compare direct (medical and drug) costs between privately insured 
U.S. employees with major depressive disorder (MDD) who had treatment-resistant 
depression (TRD) and matched antidepressant-treated MDD controls without TRD. 
METHODS: Employees with 1 inpatient or 2 outpatient/other MDD diagnoses 
(ICD-9-CM: 296.2, 296.3) during 2004–2006, ages 18–64 years, were selected from 
a claims database. Employees who initiated a third antidepressant following 2 anti-
depressant treatments of adequate dose and duration were classiﬁ ed as TRD-likely (n
 2,534). The index date was the date of ﬁ rst antidepressant. Control group was an 
age and gender matched cohort of randomly chosen antidepressant-treated employees 
with MDD without TRD. All were required to have continuous health coverage during 
the 6-month pre-index (baseline) and 12-month post-index (study) period. McNemar 
tests were used to compare baseline comorbidities. Wilcoxon signed-rank tests were 
used to compare annual per patient direct costs from third party payer perspective 
during the study period. Mental health (MH) related costs were identiﬁ ed by claims 
with MH disorder diagnosis (ICD-9-CM: 290–319) or MH-related drug costs.
RESULTS: TRD-likely employees with MDD were on average 49.2 years old and
60.7% were women. Compared with controls, TRD-likely employees had signiﬁ cantly
higher rates of MH disorders, chronic pain, ﬁ bromyalgia, but few differences in
comorbidities included in the Charlson Comorbidity Index. Average direct annual
costs were signiﬁ cantly higher for TRD-likely employees ($10,136) compared 
with controls ($7,793), $2,393 difference, p  0.0001. Average MH-related costs
were higher among TRD-likely employees ($2,714) compared with controls ($1,256),
p  .0001; the MH-related cost difference of $1,958 accounted for 62.2% of the 
direct cost difference. MH-related cost differences were attributable to differences
in drug 52.9% outpatient (929.3), inpatient (12.92%), costs. CONCLUSIONS:
TRD-likely employees with MDD had higher all-cause and MH-related direct costs
compared with matched MDD controls. Excess costs of TRD-likely patients are 
underestimated when looking only at MH-related costs.
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OBJECTIVES: Compare comorbidity proﬁ les and direct costs in older patients with
depression treated or untreated with antidepressants and matched controls without 
depression. METHODS: Administrative claims from a multi-specialty medical group
